Margaret A. Shipp, M.D.
Chief, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute
Director, Lymphoma and Myeloma Program, Dana-Farber/Harvard Cancer Center
Professor of Medicine, Harvard Medical School

Locations:

• Geffen Auditorium (Live)
• Broadcast to SMH Alfred M-459 and BA 4-316/BA 4-516
• Mayo Clinic Health System in Waycross (Video Conference)

Lunch available outside Geffen Auditorium and SMH Alfred M-459 on a first come, first serve basis

Learning Objectives:

• Review genetic bases of immune evasion, including alterations of PD-1 ligands, in lymphoid malignancies
• Identify associated approaches to immunomodulation in lymphoid malignancies
• Describe newly defined genetic subsets of diffuse large B-cell lymphoma and associated clinical implications

Financial Disclosures:
Grant/Research Support - Bristol Myers Squibb, Merck
Honoraria - Bristol Myers Squibb

Off Label/Investigational uses:
PD-1 blocking antibodies (nivolumab and pembrolizumab) - manufacturer: BMS and Merck, Off-Label use: in the context of clinical trials in specific lymphoid malignancies

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s), please go here to review disclosures.